About Biorbyt
Biorbyt is a company based in Cambridge (United Kingdom) founded in 2010 by Tillmann Ziegert. It operates as a B2B and D2C. The company has 12 employees. Biorbyt offers products and services including Primary Antibodies, ELISA Kits, Recombinant Proteins, and Molecular Biology Tools. Biorbyt operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
- Headquarter Cambridge, United Kingdom
- Employees 12
- Founders Tillmann Ziegert
- SectorsHealthcare
- Phone•••• ••••
- Website biorbyt.com
- Social LinkedIn X Facebook Instagram
- Legal Name Biorbyt Ltd
- Date of Incorporation 30 Dec, 2010
- Jurisdiction CAMBRIDGE, ENGLAND
- Employee Count12
Products & Services of Biorbyt
Biorbyt offers a comprehensive portfolio of products and services, including Primary Antibodies, ELISA Kits, Recombinant Proteins, and Molecular Biology Tools.
Antibodies for detection in life science research applications
Kits for enzyme-linked immunosorbent assays in diagnostics
Proteins produced for molecular biology and research use
Tools for DNA and RNA isolation in scientific studies
People of Biorbyt
1 people are tracked at Biorbyt (1 in leadership); the tracked headcount is 12.
| Name | Role | Group |
|---|---|---|
Tillmann Ziegert | Founder | Leadership |
Complete people profiles for Biorbyt
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of Biorbyt
Biorbyt operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Korro Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. |
Detailed competitors of Biorbyt
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Biorbyt
The website of Biorbyt (biorbyt.com) receives about 25.2K visits a month.
- Monthly visits25.2K
▲ 36.2% vs previous month
Websites whose visitors overlap most with Biorbyt. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| covalab.com | 92% | 5.3K | #3,616,510 | View details | |
| abclonal.com | 89% | 50.4K | #648,332 | View details | |
| alpco.com | 82% | 22.6K | #1,367,181 | View details | |
| abgent.com | 77% | – | – | View details | |
| abnova.com | 76% | 30.7K | #957,320 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for Biorbyt
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Biorbyt
Complete news archive for Biorbyt
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Biorbyt
10 companies that operate in the same segment as Biorbyt (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Biorbyt
Biorbyt was founded in 2010.
Biorbyt is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Biorbyt has 12 employees.
Biorbyt is a supplier of life science reagents, including antibodies, proteins, and ELISA kits for research purposes. They operate through an online platform for direct sales, offering products like molecular biology tools and viral research items. Based in the UK with offices in the US and China, Biorbyt serves global researchers and institutions in biotechnology, focusing on quality reagents for diagnostics and experiments.
Biorbyt's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Biorbyt offers Primary Antibodies, ELISA Kits, Recombinant Proteins, and Molecular Biology Tools.
Biorbyt operates through Biorbyt Ltd.